Neurocrine Biosciences, Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2025: USD 2.41 B

Neurocrine Biosciences, Inc. Revenue is USD 2.41 B for the Trailing 12 Months (TTM) ending March 31, 2025, a 21.73% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Neurocrine Biosciences, Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 1.98 B, a 23.99% change year over year.
  • Neurocrine Biosciences, Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 1.60 B, a 32.38% change year over year.
  • Neurocrine Biosciences, Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 1.21 B, a 15.51% change year over year.
  • Neurocrine Biosciences, Inc. Revenue for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 1.05 B, a 17.87% change year over year.
Key Data
Date Revenue Revenue Gross Profit Operating Income